-Asia News Network A controversy is brewing over a new cure for hepatitis C because it is extremely expensive and patients in middle-income countries like Malaysia will find it way beyond their budget. There are an estimated 400,000 Malaysians with hepatitis C, but this is probably a significant under-estimate since many people are not aware that they have the virus. Worldwide, 170 million people live with the hepatitis C virus (HCV), and every...
More »SEARCH RESULT
Basmati cess to fund cancer care in Punjab -Neel Kamal
-The Times of India BATHINDA: Basmati brought to grain markets in Punjab will now contribute to the cause of Cancer treatment as the government has imposed a cess of 0.25% on this variety of rice from this season. Punjab marketing board authorities expect to collect around Rs 19 crore from this decision depending on the arrival of basmati in the market. State agencies are hopeful of basmati yield reaching 35-36 lakh tonnes this...
More »For public health as political priority -Sujatha Rao
-The Hindu A systemic reform of the health sector in order to meet the key objectives of equity, efficiency and quality is long overdue. In this, the Central and State governments need to make interventions intelligently, decisively and strategically so that the poor reap the benefits How does Prime Minister Narendra Modi's focus on population, health and subjects like public hygiene, the facilitation of toilets and ensuring preventive health through yoga fit...
More »SC agrees on urgent hearing of drug price plea
-The Telegraph The Supreme Court today agreed to take up "as early as possible" a plea challenging a recent NDA government decision that is alleged to have paved the way for a sharp rise in the prices of life-saving drugs. Petitioner Manohar Lal Sharma, a lawyer, has demanded a CBI probe into a September 22 government order that he says frees a list of medicines from pricing control. His public interest plea alleges...
More »New drug era -Shamnad Basheer
-The Indian Express Prime Minister Narendra Modi's US visit is likely to throw up highly contentious intellectual property rights issues. Indeed, for the last several years, US drug majors and their European counterparts have lobbied hard to demonise the Indian patent regime. But the government must continue to defend the law and stand its ground. Particularly since our own industrial moguls have caved in and are less vocal about their opposition...
More »